AilsynBio, a company that uses AI to discover new medicines, held a signing event today at Hong Kong Science Park. At the event, it announced a partnership with Dong-E-E-Jiao Co., Ltd..
This partnership combines modern AI technology with traditional medicine to help create new and better drugs.
The event was attended by leaders and experts from different fields, including representatives from China Resources Pharmaceutical Group, Hong Kong Science and Technology Parks Corporation, and The University of Hong Kong, who came together to witness this important moment.
Dr. Bo Chen, Chief Scientific Officer of China Resources Pharmaceutical, noted: “This collaboration with Dong-E-E-Jiao and AilsynBio is a key initiative for China Resources Pharmaceutical in advancing the modernization of Traditional Chinese Medicine (TCM). It represents a deep integration of industry, academia, and research in the field of ‘AI + TCM’ between Mainland China and Hong Kong. We look forward to leveraging scientific research and industrial resources from both regions to overcome the challenges of TCM’s mechanisms of action and to pave an innovative path for TCM to evolve from empirical medicine to evidence-based medicine.”
Mr. Liang Zheng, Vice President of Dong-E-E-Jiao, stated: “As a core strategic product for Dong-E-E-Jiao, deepening the scientific value of Compound E-Jiao Syrup is crucial for our brand upgrade. This cooperation will strengthen the scientific foundation of our products in the field of women’s health, helping Dong-E-E-Jiao accelerate into a new stage of ‘reshaping TCM wisdom through technological innovation.'”
Mr. Pierre Wang, Managing Director of HKU Versitech Limited, stated: “HKU Versitech is honored to witness this project cooperation between HKU spin-off AilsynBio Ltd. and China Resources Pharmaceutical subsidiary Dong-E E-Jiao, a partnership that exemplifies the successful translation of Hong Kong’s top-tier academic research into high-impact industrial applications. This cooperation will continue to serve as a vital catalyst for the company’s rapid international growth and its mission to scale cutting-edge biotechnology globally.”
During the ceremony, AilsynBio and Dong-E-E-Jiao Co., Ltd. officially signed the agreement.
The signing was witnessed by Dr. Bo Chen, Chief Scientist at China Resources Pharmaceutical Group; Eric Or, Chief Ecosystem Development Officer at Hong Kong Science and Technology Parks Corporation; and Pierre Wang, Managing Director of The University of Hong Kong’s Versitech.
AilsynBio said this partnership is not just about combining modern technology with traditional medicine, but also a long-term plan for future healthcare innovation. By using AI, the collaboration aims to bring new energy to traditional medicine and help more patients.
Read More- Vingroup Starts Hanoi – Quang Ninh High-Speed Railway Project
